88IV - PR Newswire Asia's news


NUS researchers achieve breakthrough in engineering colour-sensing yeast In a new study, scientists engineered baker's yeast to sense and respond to different colours of light, enabling new ways to control cellular behaviour with red and blue light ... 2026-08-11T Biotechnology Education Food/Beverages Health Care/Hospital
Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates CAMBRIDGE, Mass. , Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today ... 2026-08-11T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery LAGUNA HILLS, Calif. and SHANGHAI , Aug. 11, 2026 /PRNewswire/ -- Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first ... 2026-08-11T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Lifespan Vision Ventures Leads Remedium Bio's Series A Financing Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. ... 2026-08-10T Banking/Financial Service Biotechnology Health Care/Hospital Medical/Pharmaceuticals
NYSE Content Update: Goldman Sachs Asset Management Launches Two New ETFs NYSE issues a pre-market daily advisory direct from the trading floor. ... 2026-08-10T Banking/Financial Service Biotechnology Computer/Electronics
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35 -ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin ... 2026-08-10T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors" — Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, ... 2026-08-10T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer HONG KONG , Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) ... 2026-08-10T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
2026 Global Health Summit Opens in Hong Kong -- Global Healthcare Leaders Convene: Bringing Breakthroughs to Patients HONG KONG , Aug. 10, 2026 /PRNewswire/ -- The 2026 Global Health Summit ("GHS 2026"), jointly hosted by New Frontier Group ("New Frontier") and the Hong Kong Investment Corporation ... 2026-08-10T Biotechnology Computer/Electronics Health Care/Hospital Medical/Pharmaceuticals
Second PIC/S GMP Certification \| Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections SHANGHAI , Aug. 10, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary ... 2026-08-10T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Biotechnology